Episode 325: 1+1 =3 Numeracy and shared-decision making – PART II

In episode 325, Mike and James continue their discussion about numbers and how to communicate risks. We discuss if people even want shared decisions and then if they do, what talk tools to use to facilitate that discussion.

Show notes

FRACTURES Read more »

Episode 324: 1+1 =3 Numeracy and shared-decision making

In episode 324, Mike and James start a discussion about why numbers and our ability to communicate risks, benefits and harms to patients is crucial in today’s health care environment. Unfortunately, we find that many of us struggle with these concepts.

Show notes

Slides

Episode 323: LABA and steroids in asthma – is there any risk?

In episode 323, James and Mike go over two new studies that have looked at the risk of using LABAs in combination with inhaled corticosteroids in both adults and children. Bottom line – no increased risk, but also not a lot of benefit either.

Show notes

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma Read more »

Episode 322: PrEP’d for HIV prevention

In episode 322, Mike and James go over a new Tools for Practice that looked at the use of a combination product that may reduce the risk of HIV. It definitely seems to work but adherence is the key.

Show notes

Tools for Practice Read more »

Episode 321: A couple of new studies that will confirm or change your practice

In episode 321, James and Mike discuss two interesting studies. One is on the duration of antibiotics for community-acquired pneumonia and the other about the impact of total knee replacement on the overall quality of life. Interestingly, the results of these studies were different although that may have been the fact that one was on pneumonia and the other on TKR.

Show notes Read more »

Episode 320: PREMIUM – Our spin on the latest type 2 diabetes publications

In episode 320, Mike and James PREMIUM out yet again and talk about 3 new diabetes publications that our listeners have asked us about.

Show notes

1) LEADER Study

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2016; 375:311-22 Read more »

Episode 319: Listener questions and some questionable answers – PART IV

In episode 319, Mike and James begin questioning the number of questions they are having to answer but plough forward and talk about confidence intervals, anticoagulation bridging, hormone replacement and finally bring it all home with comments on DRE. 

Show notes Read more »

Episode 318: Listener questions and some questionable answers – PART III

In episode 318, Mike and James attempt to answer even more questions. We run the spectrum from steroid injections, to repeat bone density measurements, to vortioxetine, generic drugs, and sitagliptin. Bottom line - please stop going to industry sponsored CME.

Show notes

1) Generic drugs Read more »